MedImmune, the global biologics research and development arm of AstraZeneca, announced today that it has entered into two umbrella Cooperative Research and Development Agreements with the National Cancer Institute , a part of the National Institutes of Health , that are focused on immunotherapy and tumor targeted therapies for cancer. These agreements will leverage technological know-how and resources from each organization to support preclinical and clinical research and development activities in these areas.
http://ift.tt/1JfF0Jm
http://ift.tt/1JfF0Jm
No comments:
Post a Comment